Health Business Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Business Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Angiogenesis
Ocular Biopharmaceutical Company Charlesson Announces $1.6MM in New Funding and Upcoming Presentations at the Association for Research in Vision and Ophthalmology
May 9th, 2008
Charlesson LLC, an ocular biopharmaceutical company, announced that it is the recipient of two Small Business Innovative Research (SBIR) awards from the National Institutes of Health (NIH). The two grants total approximately $1,600,000 and will support development of a nanoparticle-formulated therapy for eye disease as well as commercialization of a preclinical genetic animal model for Age- Related Macular Degeneration (AMD). Dr. Rafal Farjo, Director of Research and Development at Charlesson, is principal investigator on both grants. Mike Moradi, Chief Executive Officer of Charlesson said, "We are proud to be NIH's partner in success. These competitive grant awards...
Source: Health Business Week (2008-05-09)
|
